Last update: March 20, 2020
Blood product transfusion thresholds must be strictly followed, and all product release outside of these thresholds will require approval of pathology staff
Blood products to be on hold for procedure should be ordered as usual, but for inventory control and to minimize the chance of wastage will remain physically in the blood bank until they need to be transfused (outside of massive transfusions).
As the front-line stewards of a non-renewable and potentially finite resource with direct knowledge of the supply of blood products available, all final decisions about the release of blood products are at the final discretion of the attending pathologist.
During critical times of blood product shortage, the RBC transfusion thresholds will be lowered: first for stable patients who are not bleeding, and then if necessary, for patients with pre-existing cardiovascular disease or those with acute coronary syndrome.
These documents and content on this website are guidelines during the COVID-19 pandemic. Because new information is released rapidly, these documents can be updated or changed at any time. These documents are in no way to be considered as a standard of care and the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The information in these documents is provided with no guarantees, accuracy, or timeliness. All content in these documents and website are for informational purposes only and do not constitute the providing of medical advice.